{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"10"}]}],"title":"TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"9"}]}],"title":"Grade 3-5 TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}],"title":"Grade 5 TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"8"}]}],"title":"JCARH125-Related TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"7"}]}],"title":"JCARH125-Related Grade 3-5 TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}]}],"title":"JCARH125-Related Grade 5 TEAE"}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"description":"TEAE is defined as an AE that starts any time from initiation of JCARH125 administration through and including 90 days following the JCARH125 infusion graded using the NCI Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. Any AE occurring after the initiation of another anticancer treatment will not be considered a TEAE. Grade 3=Severe; Grade 4=Life-threatening; and Grade 5=death.","groups":[{"description":"JCARH125 IV at dose level 600 x 10\\^6 consisting of CD3+CAR+T cells expansion","id":"OG000","title":"Phase 2 600 x 10^6 Cells"},{"description":"JCARH125 IV at dose level 600 x 10\\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy","id":"OG001","title":"Phase 2a 600 x 10^6 Cells Anti-BCMA"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants who received at least one infusion of JCARH125 in phase 2 and in phase 2a","reportingStatus":"POSTED","timeFrame":"From the time of JCARH125 infusion to 90 days following the infusion (Up to 90 days)","title":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity in Phase 2 and Phase 2a","type":"SECONDARY","unitOfMeasure":"Participants"}